紫杉醇脂质体联合顺铂治疗48例晚期非小细胞肺癌疗效观察

目的观察紫杉醇脂质体与普通紫杉醇联合顺铂（DDP）治疗晚期非小细胞肺癌（NSCLC）的近期疗效和不良反应。方法晚期非小细胞肺癌患者96例，随机被分为治疗组48例和对照组48例，治疗组采用紫杉醇脂质体75mg／m^2（静脉滴注，第1、8天），对照组采用普通紫杉醇75mg／m^2（静脉滴注，第1、8天），两组均联合顺铂25mg／m^2（静脉滴注，第1～3天）化疗，21d为1个周期，每2个周期按RECIST标准评价疗效。结果治疗组完全缓解（CR）1例，部分缓解（PR）20例，稳定（SD）19例，进展（PD）8例，总有效率为43．8％，临床受益率为83．3％。对照组CR0例，PR19例，SD20例，PD9例，总有效率为39．6％，临床受益率为81．3％。两组总有效率、血液学毒性的发生率比较，差异无统计学意义（P〉0．05）。治疗组患者消化道反应、皮疹、肌肉痛的发生率低于对照组，差异有统计学意义（P〈0．05）。结论紫杉醇脂质体联合DDP治疗晚期NSCLC近期疗效较好，消化道反应、皮疹、肌肉痛的发生率较普通紫杉醇联合顺铂轻。

Clinical observation of paclitaxel - liposome combined with cisplatin in the treatment of 48 cases of advanced non -small cell lung cancer

Objective To investigate the efficacy and toxity of paclitaxel liposome and traditional paclitaxol plus cisplatine in the treatment of advanced non - small cell lung cancer. Methods Ninety six patients were randomized into two groups, patients in treatment group were given paclitaxel liposome 75 mg/m^2, ivgtt, on day 1,8 plus DDP 25 mg/m^2 , ivgtt, on day 1 to 3, and patients in control group were given paclitaxel 75 mg/m^2, ivgtt, on day 1,8 plus DDP 25 mg/m^2, ivgtt, on day 1 to 3. Treatment was repeated every 21 days. Treatment efficacy was evaluated every two cycles based on the RESIST standard. Results The total effective rates of treatment group and control group were 43.8% and 39. 6% （ P 〉 0.05）, and the disease control rates were 83.3% and 81.3% （ P 〉 0. 05）, respectively. The total effective rates and rates of neutropenia and thrombocytopenia were not significantly different in the two groups, whereas more patients in the control group suffered from nausea and vomiting, skin rash and courbature than in treatment group （P 〈 0. 05）. Conclusions Paclitaxel liposome combined with DDP is an effective treatment regiment in patients with advanced non - small cell lung cancer suffered from nausea and vomiting, skin rash and courbature.